ATC codes:
L02AE02
Indication
Malignant neoplasms of prostate
ICD11 code:
2D32.Z
INN
Leuprorelin
Medicine type
Chemical agent
List type
Complementary
Formulations
Parenteral > General injections > IM:
7.5 mg in prefilled syringe ;
22.5 mg in prefilled syringe
EML status history
First added in 2015
(TRS
994)
Sex
Male
Age
Adolescents and adults
Therapeutic alternatives
Medicines within the same pharmacological class can be used
Patent information
Patents have expired in most jurisdictions
Read more
about patents.
Summary of evidence and Expert Committee recommendations
In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, leuprorelin (with a square box) was added to the complementary list of the EML for use in the treatment of metastatic prostate cancer. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for metastatic prostate cancer is attached.